The journey of canakinumab; on- and off-label indications
The role of interleukin-1 (IL-1) has been studied in many diseases, ranging from auto-inflammatory diseases to malignancies, and much has been discovered. There are currently four IL-1 inhibitors available, but only two have been approved in Europe: the receptor antagonist anakinra, and the IL-1b selective inhibitor canakinumab. The aim of this paper is to summarise the on- and off-label use of canakinumab (ILARIS®).
Copyright (c) 2019 Daniela Marotto, Alberto Batticciotto, Angela Ceribelli, Piercarlo Sarzi Puttini
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.